FDA SUPPLEMENTAL USE REVIEW STREAMLINING ENDORSED BY DANA FARBER's CHABNER; AGENCY SHOULD PUBLICIZE CLINICAL TRIAL INFORMATION -- KIDNEY CANCER ASSOCIATION
Executive Summary
Supplemental indications should be reviewed under a streamlined process at FDA, former National Cancer Institute Cancer Treatment Director Bruce Chabner, MD, recommended to the House Commerce/Health Subcommittee Feb. 27.